<DOC>
	<DOC>NCT01211821</DOC>
	<brief_summary>The purpose of the study is to assess the effects of BMS-914392 administration on the pharmacokinetics of a single-dose of metoprolol in healthy subjects.</brief_summary>
	<brief_title>Effect of BMS-914392 on Pharmacokinetics of Metoprolol</brief_title>
	<detailed_description>Protocol designed to evaluate the potential for a drug-drug-interaction</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations. Subjects genotyped as Intermediate, Extensive or Ultrarapid CYP2D6 metabolizers Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy Any significant acute or chronic medical illness. Current or recent (within 3 months of study drug administration) gastrointestinal disease. Current or history of neurological diseases or psychiatric disorders, cardiovascular diseases, and bronchospastic diseases. CYP2D6 poor metabolizers based on genotype</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>